Research & Development
We are actively driving research and development globally with partnerships specializing in the fields of interest. Our focus is to develop botanical based pharmaceutical medicine for in-market use globally
Psilocybin
• Phase II Clinical Trial approved March 2022 in South Africa for the use of Psilocybin API for the treatment of Major Depressive Disorder
• Psilocybin cultivation research and development application submitted in South Africa on current 23 hectare property
Cannabidiol (CBD) for the treatment of Traumatic Brain Injury
• Utilizing CBD API for the treatment of TBI in sports related head injuries
• Phase 1 Clinical Trial submission expected Q3 2022 with commencement late 2022
Cannabidiol (CBD) for the treatment Schizophrenia
• Utilizing CBD API in combination with other treatments in the reduction of relapse schizophrenia
• Phase 1 Clinical Trial submission expected Q3 2022 with commencement in 2023